

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



PuraPharm

PURAPHARM CORPORATION LIMITED

培力農本方有限公司

(Formerly known as 培力控股有限公司 in Chinese)

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1498)

CLARIFICATION ANNOUNCEMENT

GRANT OF SHARE OPTIONS

Reference is made to the announcement of PuraPharm Corporation Limited (the “**Company**”) dated 29 December 2022 in relation to the grant of Options (the “**Announcement**”). Unless otherwise stated, capitalised terms used herein shall have the same meaning as those defined in the Announcement.

The Company would like to clarify that, due to rounding presentation in the Announcement, the exercise price of the Options is HK\$1.29₂, which represents the highest of: (i) the closing price of HK\$1.28 per Share as stated in the Stock Exchange’s daily quotation sheet on the Date of Grant; (ii) the average closing price of HK\$1.29₂ per Share as stated in the Stock Exchange’s daily quotation sheets for the five trading days immediately preceding the Date of Grant; and (iii) the nominal value of US\$0.1 per Share.

Save as disclosed in this announcement, the content of the Announcement remains unchanged.

By order of the Board
PuraPharm Corporation Limited
Chan Yu Ling, Abraham
Chairman

Hong Kong, 30 December 2022

As at the date of this announcement, the executive Directors of the Company are Mr. Chan Yu Ling, Abraham, Ms. Man Yee Wai, Viola and Dr. Norimoto Hisayoshi; and the independent non-executive Directors of the Company are Mr. Ho Kwok Wah, George, Dr. Leung Lim Kin, Simon and Prof. Tsui Lap Chee.